FEATURE
New Alzheimer’s Drugs Trialled by Re:Cognition
New clinical trials launched by Re:Cognition Health to slow the progression of Alzheimer’s and improve cognitive symptoms are now underway. Here Tomorrow’s Care find out more.
A cognitive health clinic in the south of England is currently trialling new medications designed to slow down the progression of Alzheimer’s disease.
Three branches of Re:Cognition Health, based in London, Guildford and Plymouth, are enrolling members
Transforming Cognitive
Performance Re:Cognition Health aim to transform and optimise cognitive performance through education, clinical excellence and access to emerging treatments. The clinic specialises in all aspects of cognitive function, offering advice and treatment of traumatic brain injuries, stroke and common problems like headaches, dizziness, concussion and migraines. It also specialises in management and treatment of conditions like ADHD, autism and dyslexia.
- 44 -
of the public into international final phase clinical trials for the medications, which have been specially designed to slow the progression of Alzheimer’s and improve cognitive symptoms.
Existing treatments can help only to manage symptoms and temporarily boost memory and other cognitive symptoms and so this trial is significant in this field.
The clinical trials underway are also targeting individuals with mild symptoms of cognitive impairment or no symptoms at all, but who have been identified as being in a high risk group to develop Alzheimer’s disease.
Speaking about the study Dr Emer MacSweeney, CEO and Medical Director of Re:Cognition Health commented: “These studies provide those shown to be at significant risk with an opportunity to gain early access to new medications designed
Some Useful Facts
• There are 850,000 people in the UK with some form of dementia.
• Alzheimer’s disease is one of the most common causes of dementia.
• Two thirds of people with dementia are women.
• 42,000 people under the age of 65 have dementia (young-onset dementia).
to delay the time at which they might otherwise develop memory loss and related symptoms.
With no cure for dementia currently available there is a lot riding on the outcome of these trials, which have been launched with the aim of improving the quality of life of those living with a diagnosis of Alzheimer’s disease and those showing early signs of mild cognitive impairment.
www.recognitiontrials.co.uk www.tomorrowscare.co.uk
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56